title: Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242.
abstract: The size and composition of the circulating bile acid (BA) pool are important factors in regulating the human gut microbiota. Disrupted regulation of BA metabolism is implicated in several chronic diseases. Bile salt hydrolase (BSH)-active Lactobacillus reuteri NCIMB 30242, previously shown to decrease LDL-cholesterol and increase circulating BA, was investigated for its dose response effect on BA profile in a pilot clinical study. Ten otherwise healthy hypercholesterolemic adults, recruited from a clinical trial site in London, ON, were randomized to consume delayed release or standard release capsules containing L. reuteri NCIMB 30242 in escalating dose over 4 weeks. In another aspect, 4 healthy normocholesterolemic subjects with LDL-C below 3.4 mmol/l received delayed release L. reuteri NCIMB 30242 at a constant dose over 4 weeks. The primary outcome measure was the change in plasma BA profile over the intervention period. Additional outcomes included circulating fibroblast growth factor (FGF)-19, plant sterols and LDL-cholesterol as well as fecal microbiota and bsh gene presence. After one week of intervention subjects receiving delayed release L. reuteri NCIMB 30242 increased total BA by 1.13 ± 0.67 μmol/l (P = 0.02), conjugated BA by 0.67 ± 0.39 μmol/l (P = 0.02) and unconjugated BA by 0.46 ± 0.43 μmol/l (P = 0.07), which represented a greater than 2-fold change relative to baseline. Increases in BA were largely maintained post-week 1 and were generally correlated with FGF-19 and inversely correlated with plant sterols. This is the first clinical support showing that a BSH-active probiotic can significantly and rapidly influence BA metabolism and may prove useful in chronic diseases beyond hypercholesterolemia.
authors.affiliation: a Biomedical Technology and Cell Therapy Research Laboratory; Dept. of Biomedical Engineering; Faculty of Medicine ; McGill University ; Montreal , QC Canada.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Martoni
authors.forename: Alain
authors.initials: A
authors.lastname: Labbé
authors.forename: Jorge G
authors.initials: JG
authors.lastname: Ganopolsky
authors.forename: Satya
authors.initials: S
authors.lastname: Prakash
authors.forename: Mitchell L
authors.initials: ML
authors.lastname: Jones
mesh_terms: D000328:Adult; D000368:Aged; D000581:Amidohydrolases / Q000378:metabolism*; D001647:Bile Acids and Salts / Q000378:metabolism*; D005260:Female; D005346:Fibroblast Growth Factors / Q000378:metabolism*; D006801:Humans; D007408:Intestinal Absorption; D052200:Limosilactobacillus reuteri / Q000201:enzymology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D019936:Probiotics / Q000008:administration & dosage*; D011897:Random Allocation; D013261:Sterols / Q000378:metabolism*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001647:Bile Acids and Salts; C117476:FGF19 protein, human; D013261:Sterols; D005346:Fibroblast Growth Factors; D000581:Amidohydrolases; C023154:choloylglycine hydrolase
keywords: bile acid metabolism; bile salt hydrolase; cholesterol; fibroblast growth factor-19; probiotic